DuraGraft Receives SGK National Reimbursement in Turkey
DuraGraft a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure. [...]
Marizyme, Inc. Agrees to Acquire All Assets of Somahlution
JUPITER, FLA, December 17, 2019 Marizyme, Inc. (Marizyme or the Company), a publicly traded (OTC:MRZM) company focused on acquiring late-stage drug and medical device assets to develop [...]
UK's NICE Publishes a Medtech Innovation Briefing on DuraGraft.
NICE Publishes a Medtech Innovation Briefing (MIB) on DuraGraft for Preserving Vascular Grafts and Associated Endothelium used in Coronary Artery Bypass Graft (CABG) Surgery. [...]
Peer-Reviewed Study Demonstrates the Use of DuraGraft May Reduce VGF-related Complications Post-CABG
January 22, 2019 - Somahlution’s peer-reviewed publication suggests CABG patients may benefit long-term clinical
outcomes following surgery when treated with DuraGraft; First-in-class intraoperative vascular graft
treatment shown to reduce the risk of graft failure. [...]
Somahlution Announces European Hospital in Rome to Participate in European DuraGraft® Registry
March 27, 2018 - Somahlution Announces European Hospital in Rome to Participate in European DuraGraft® Registry [...]
Somahlution Announces Site Initiation and Patient Enrollment in United Kingdom for European DuraGraft Registry
February 12, 2018 - Somahlution Announces Site Initiation and Patient Enrollment in United Kingdom for European DuraGraft Registry [...]
Somahlution Announces DuraGraft Registry Initiation at Leading Cardiac Surgery Hospitals in Germany
May 26, 2017 - Somahlution Announces DuraGraft Registry Initiation at Leading Cardiac Surgery Hospitals in Germany [...]
Somahlution Announces Medical University of Vienna as First Austrian Site to Participate in DuraGraft Registry
May 5, 2017 - Somahlution Announces Medical University of Vienna as First Austrian Site to Participate in DuraGraft Registry [...]
Somahlution Announces Multiple Site Initiation and Patient Enrollment in Spain for European DuraGraft Registry
February 1, 2017 - Somahlution Announces Multiple Site Initiation and Patient Enrollment in Spain for European DuraGraft Registry [...]
Research Shows Promising Long-Term Outcomes For New Vascular Graft Treatment
Somahlution recently released results of a study on long-term outcomes in procedures using their vascular graft treatment product, Duragraft. The company, based in Jupiter, Florida, is celebrating the highly encouraging results [...]
Novel treatment to prevent vein graft failure confers improved outcomes after CABG
Researchers conducted a retrospective, nonrandomized real-world study of 2,436 patients who had CABG with at least one saphenous vein graft. In the cohort, 1,036 were treated with the vascular graft treatment designed to protect [...]
DuraGraft Vascular Graft Evaluated to Prevent Vein Graft Failure After CABG
Dr. Haime discusses an abstract about Somahlution DuraGraft during a rapid response session at the 2016 annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS; 1–5 October, Barcelona, Spain) [...]
Intraoperative Vascular Graft Treatment Shown to Reduce Risk of Graft Failure
Somahlution, a global biotechnology company leading the development of products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced presentation [...]
Somahlution announced the presentation of new data showing the its DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery. Results were presented today [...]
Somahlution Reveals Positive Study Results Showing Efficacy of DuraGraft
Somahlution's DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery, the company said at the European Association for Cardio-Thoracic Surgery [...]